deferoxamine has been researched along with Colorectal Cancer in 8 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 8.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| "However, the effect of DFX on cancer metastasis and the related mechanisms are not well established." | 5.40 | Deferoxamine enhances cell migration and invasion through promotion of HIF-1α expression and epithelial-mesenchymal transition in colorectal cancer. ( Jiang, B; Ma, F; Peng, Y; Shi, X; Wang, J; Wu, Y; Yan, Q; Zhang, W; Zhao, Y, 2014) |
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 4.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| " The relative luciferase activities were measured under various durations of hypoxia (6, 12, 18, and 24 h), O2 concentrations (1, 2, 4, 8, and 16 %), and various concentrations of deferoxamine mesylate (20, 40, 80, 160, and 320 µg/mL growth medium)." | 3.80 | Detailed assessment of gene activation levels by multiple hypoxia-responsive elements under various hypoxic conditions. ( Hata, H; Inubushi, M; Jin, YN; Kitagawa, Y; Murai, C; Saga, T; Takeuchi, Y; Tsuji, AB, 2014) |
| " The chemically linked heteroconjugate of MAb 454A12 (murine IgG1 recognizing human transferrin receptor) and 317G5 (murine IgG1 recognizing a 42-kDa tumor-associated glycoprotein) was particularly inhibitory toward human colorectal cancer cell lines, and the iron-chelating agent deferoxamine was found to augment inhibition of tumor cell growth by this antigen fork." | 3.69 | Murine bispecific antibody 1A10 directed to human transferrin receptor and a 42-kDa tumor-associated glycoprotein. ( Hsieh-Ma, ST; Reeder, J; Ring, DB; Shi, T, 1996) |
| "However, the effect of DFX on cancer metastasis and the related mechanisms are not well established." | 1.40 | Deferoxamine enhances cell migration and invasion through promotion of HIF-1α expression and epithelial-mesenchymal transition in colorectal cancer. ( Jiang, B; Ma, F; Peng, Y; Shi, X; Wang, J; Wu, Y; Yan, Q; Zhang, W; Zhao, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, B | 1 |
| Mai, Z | 1 |
| Ye, Y | 1 |
| Song, Y | 1 |
| Zhang, M | 1 |
| Yang, X | 1 |
| Xia, W | 1 |
| Qiu, X | 1 |
| Bragg, MA | 1 |
| Breaux, WA | 1 |
| M'Koma, AE | 1 |
| Zhang, Y | 1 |
| Yapryntseva, MA | 1 |
| Vdovin, A | 1 |
| Maximchik, P | 1 |
| Zhivotovsky, B | 1 |
| Gogvadze, V | 1 |
| Zhang, W | 1 |
| Wu, Y | 1 |
| Yan, Q | 1 |
| Ma, F | 1 |
| Shi, X | 1 |
| Zhao, Y | 1 |
| Peng, Y | 1 |
| Wang, J | 1 |
| Jiang, B | 1 |
| Takeuchi, Y | 1 |
| Inubushi, M | 1 |
| Jin, YN | 1 |
| Murai, C | 1 |
| Tsuji, AB | 1 |
| Hata, H | 1 |
| Kitagawa, Y | 1 |
| Saga, T | 1 |
| Song, S | 1 |
| Christova, T | 1 |
| Perusini, S | 1 |
| Alizadeh, S | 1 |
| Bao, RY | 1 |
| Miller, BW | 1 |
| Hurren, R | 1 |
| Jitkova, Y | 1 |
| Gronda, M | 1 |
| Isaac, M | 1 |
| Joseph, B | 1 |
| Subramaniam, R | 1 |
| Aman, A | 1 |
| Chau, A | 1 |
| Hogge, DE | 1 |
| Weir, SJ | 1 |
| Kasper, J | 1 |
| Schimmer, AD | 1 |
| Al-awar, R | 1 |
| Wrana, JL | 1 |
| Attisano, L | 1 |
| Shi, T | 1 |
| Hsieh-Ma, ST | 1 |
| Reeder, J | 1 |
| Ring, DB | 1 |
| Ryser, JE | 1 |
| Jones, RM | 1 |
| Egeli, R | 1 |
| Pélegrin, A | 1 |
| Rose, K | 1 |
| Kurt, AM | 1 |
| Perin, M | 1 |
| Broquet, PE | 1 |
| Ambrosetti, P | 1 |
| Fisch, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy[NCT00990587] | Phase 1 | 20 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for deferoxamine and Colorectal Cancer
| Article | Year |
|---|---|
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Topics: Acute Disease; Administration, Oral; Benzoates; beta Catenin; Cell Line, Tumor; Cell Proliferation; | 2011 |
7 other studies available for deferoxamine and Colorectal Cancer
| Article | Year |
|---|---|
The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Deferoxamine; | 2022 |
Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational and Transformational Risks Posed by Exogenous Free Hemoglobin Alpha Chain, A By-Product of Extravasated Erythrocyte Macrophage Erythrophagocytosis.
Topics: Antioxidants; Colorectal Neoplasms; Deferoxamine; Erythrocytes; Haptoglobins; Humans; Inflammatory B | 2023 |
Modeling hypoxia facilitates cancer cell survival through downregulation of p53 expression.
Topics: Apoptosis; Caspase 3; Cell Survival; Colorectal Neoplasms; Cytochromes c; Deferoxamine; Down-Regulat | 2021 |
Deferoxamine enhances cell migration and invasion through promotion of HIF-1α expression and epithelial-mesenchymal transition in colorectal cancer.
Topics: Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; | 2014 |
Detailed assessment of gene activation levels by multiple hypoxia-responsive elements under various hypoxic conditions.
Topics: Animals; Cell Hypoxia; Colorectal Neoplasms; Deferoxamine; Fireflies; Gene Expression; HCT116 Cells; | 2014 |
Murine bispecific antibody 1A10 directed to human transferrin receptor and a 42-kDa tumor-associated glycoprotein.
Topics: Animals; Antibodies, Bispecific; Antibody Specificity; Antigens, Tumor-Associated, Carbohydrate; Bin | 1996 |
Colon carcinoma immunoscintigraphy by monoclonal anti-CEA antibody labeled with gallium-67-aminooxyacetyldeferroxamine.
Topics: Aged; Carcinoembryonic Antigen; Colorectal Neoplasms; Deferoxamine; Female; Gallium; Gallium Radiois | 1992 |